Condition: Urinary Tract Infections · Sponsor: GlaxoSmithKline
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Lenexa, Kansas, United States | Recruiting |
| GSK Investigational Site | Secaucus, New Jersey, United States | Recruiting |
| GSK Investigational Site | Rochester, New York, United States | Recruiting |
| GSK Investigational Site | Weatherford, Texas, United States | Recruiting |
| GSK Investigational Site | Seattle, Washington, United States | Recruiting |
| GSK Investigational Site | Wenatchee, Washington, United States | Recruiting |
| GSK Investigational Site | Johannesburg, South Africa | Recruiting |
| GSK Investigational Site | Soshanguve, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06702449